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There is limited information on how to perform in vitro release tests for intravenously 
administered parenteral formulations and how to relate the in vitro release with an in vivo 
pharmacokinetic parameter after the administration of the formulation. In this study, the 
effect of hydrodynamics (using sample and separate and continuous flow conditions) and 
medium components (synthetic surfactants, albumin and buffers) on the release of 
Amphotericin B from the liposomal Ambisome® formulation were investigated. 
Pharmacokinetic modeling of plasma concentration profiles from healthy subjects 
administered Ambisome® was used to estimate the in vivo release rate constant of drug from 
the formulation in order to compare it with the in vitro release profiles. With the estimated in 
vivo and in vitro release rate constants, release profiles were generated. Two approaches were 
followed: comparison of in vivo and in vitro release rate constants and comparison of the area 
under the percent release-time curve from observed in vitro release data and simulated in vivo 
release data. Albumin was found to be most critical factor for the release of the drug by 
having a negative effect on the amount of Amphotericin B released. The release profiles 
obtained with the sample and separate method in both Krebs Ringer buffer- and Phosphate 
Saline buffer - albumin 4.0% w/v were predictive of the in vivo release profiles in healthy 
subjects. Determining the factors affecting drug release from parenteral formulations and 
relating the release profiles to a pharmacokinetic parameter in vivo supports the development 
of in vitro in vivo relations for parenteral products.
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1. Introduction
The timescale of therapeutic effect of parenterals can be controlled, to a certain extent, by the 
type of the formulation (e.g. suspensions, liposomes). Liposomes, which are the focus of this 
study, are vesicles formed by one or more phospholipid bilayer(s) with an internal aqueous 
phase and a typical size ranging from 25 nm to 2.5 μm that could encapsulate or integrate 
drugs in their structure [1]. There is a lack of regulatory guidance with specific test conditions 
for in vitro release tests for liposomes. Shah et. al. [2] recommended the use of the flow 
through cell dialysis adapter in the flow through cell apparatus. The Food and Drug 
Administration (FDA) guidelines for liposomal products only states that a validated release 
test should be performed with a suitable release medium (e.g. plasma, or simulated 
physiological or non-physiological medium) and with suitable agitation [3]. In vitro release 
from liposomes has been studied using several methods including dialysis and sample and 
separate methods [4-7]. In sample and separate methods, a critical step is the separation of the 
released drug from the liposomes. Ultracentrifugation can be used, but the long times 
required to pellet small liposomes (< 100 nm) makes this technique unsuitable to capture a 
snapshot of drug release for construction of a release profile [8-13]. Solid phase extraction 
(SPE) provides a quicker separation and the drug still entrapped in the liposomes can also be 
quantified, making it possible to calculate the release based on the quantity of drug remaining 
in the formulation; this approach is particularly suitable if the released drug has degradation 
or solubility issues [14, 15]. 
For the development of an in vitro release test for liposomes, the first step is to consider 
selection of relevant conditions: a suitable release medium based on the physicochemical 
properties of the drug, suitable hydrodynamics and an adequate dialysis membrane with an 
appropriate molecular weight cut-off (MWCO) if needed. In vitro hydrodynamics would 
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relate to the agitation applied in the form of predominantly rotational flow, provided by e.g. a 
magnetic stirrer or by a predominantly linear flow (e.g. the flow through cell apparatus) [2].
Amphotericin B (AmB) is a polyene anti-fungal antibiotic, which is highly protein bound in 
vivo [16]. Ambisome® is a commercially available liposomal parenteral formulation of AmB. 
Ambisome® liposomes have a diameter less than 100 nm and consist of a unilamellar bilayer 
with AmB intercalated within the membrane, where the drug is an integral part of the 
liposomal structure [17]. Ambisome® is administered by intravenous infusion and indicated 
for treatment of severe systemic mycoses [18]. Such patients can be critically ill and 
frequently exhibit hypoalbuminaemia.
The release of polydiacetylene (a colorimetric compound) from liposomes with the same 
charge and of similar composition as Ambisome® (negatively charged liposomes of 
dimyristoylphosphatidylcholine and polymerized 10, 12-pentacosadiynoic acid), using 
hexadecyltrimethylammonium bromide (CTAB; cationic surfactant), sodium lauryl sulfate 
(SLS; anionic surfactant) and Triton 100X (non-ionic surfactant), has been reported [19]. 
CTAB produced the fastest release followed by Triton 100X. The release with SLS was 
minimal but the addition of NaCl increased the amount released; as for charged surfactants, 
an increase in the ionic strength decreased the critical micellar concentration (CMC), while 
non-ionic surfactants were not affected [20]. Therefore, the buffer used in the release test is 
another factor to investigate. Mechanistically, it has been reported that surfactant monomers 
partition into the surface of the liposomes, then surfactant-saturated vesicles and lipid-
saturated micelles start to coexist followed by the lipids forming mixed micelles with the 
surfactants eventually leading to liposomal disruption [21-23]. 
Whereas in vitro release tests are frequently conducted for quality control purposes, in vitro 
release test conditions which reflect the in vivo performance are desirable. For parenteral 
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formulations administered intravenously such as liposomes, pharmacokinetic (PK) models of 
formulated and released drug circulating concurrently could be exploited to estimate the in 
vivo release profile, in order to guide in vitro release test development.
In previous studies, biorelevant media representing the plasma albumin concentration [24, 
25] and media able to provide clinically relevant AmB solubility values using synthetic 
surfactants [25] have been developed. These media were developed based on the AmB active 
pharmaceutical ingredient (API) and tests are needed to investigate how these media will 
affect the release from the liposomal formulation. Ambisome® liposomes are negatively 
charged [17] and this will define how surfactants, depending on their charge, will interact 
with them. 
The aims of this study were a) to investigate how media composition including synthetic 
surfactants, buffers, and protein content (bovine serum albumin (BSA) concentration), and 
hydrodynamic conditions affect the release of AmB from Ambisome® liposomes and b) using 
PK modelling of published data of AmB plasma concentrations from healthy subjects to 
estimate in vivo release rates and area under the curve of the percent released-time profile, in 
order to identify clinically relevant in vitro test conditions for a parenteral liposomal 
formulation using Ambisome® as model formulation. 
2. Materials and Methods
2.1. Materials
AmB analytical standard (87.8%), methanol (MeOH) high performance liquid 
chromatography (HPLC) grade, formic acid mass spectrometry grade, NaOH, MgCl2, CaCl2, 
CTAB, and NaHCO3 were obtained from Sigma Aldrich (Germany); AmB API powder 
(85%) from Cayman Chemical (USA); BSA protease free powder fraction V, dimethyl 
sulfoxide (DMSO), dextrose, SLS, Na2HPO4, NaH2PO4, KH2PO4, NaCl and KCl from Fisher 
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Scientific (USA); Tween 80 from Amresco (USA); GF/D (pore size 2.7 μm, 25 mm 
diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) filters from Whatman (UK); 
regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus (UK); cellulose 
ester dialysis tubing of 300 kDa MWCO from Spectrum Labs® (USA) and Sep – Pak® Vac 
3cc (500 mg) tC18 SPE column from Waters (Massachusetts, USA). 
2.2. Sample treatment of AmB from release media
The SPE method to separate liposomal AmB from released AmB was a modification of the 
method reported by Egger et al [15]. Briefly, the SPE column was conditioned with 1.0 mL 
of MeOH followed by 1.0 mL of water. 1.0 mL of sample was passed through the column 
and the eluate was collected in a clean vial (liposomal AmB), the column was washed with 
2.0 mL of water and collected in the same tube, (remaining liposomal AmB in the column). 
1.0 mL of methanol was passed through the column to elute the AmB retained in the column 
(released AmB). In the case of samples with proteins, samples were treated as described 
previously [24]. Briefly, proteins were precipitated by adding 2 volumes of methanol to 1 
volume of the sample followed by mixing in a vortex for 30 seconds and then centrifuged for 
10 min at 12,000 rpm and 5°C in an Eppendorf centrifuge. Supernatant was filtered through a 
0.45 μm RC filter before injection to the HPLC.
2.3. Chromatographic conditions for the analysis of AmB from release media
The chromatographic method to quantify AmB was described previously [24]. Briefly, AmB 
was quantified by HPLC with a C18 Waters Sunfire column (Ireland) 150 x 46 mm 5μm at 
25°C. The mobile phase was formate buffer (50 mM; pH = 3.2): MeOH (25:75, v/v); the flow 
rate was 1 mL/min and AmB was detected at λ = 406 nm. The UV spectrum was recorded 
from 300 to 450 nm. Freshly prepared standard solutions (0.5 – 15 μg/mL) in the 
corresponding medium were prepared by appropriate dilution of a 500 μg/mL stock solution 
7
of AmB analytical standard in 1:1 MeOH: DMSO v/v. The limit of detection (LoD) and the 
limit of quantification (LoQ) were 0.12 and 0.37 μg/mL, respectively.
2.4. In vitro release studies of AmB from Ambisome® formulation
The factors investigated for the development of the in vitro release studies were: i) the 
composition of the release media: type of buffer, BSA concentration and synthetic surfactant 
concentration, and ii) the hydrodynamic conditions in terms of the method used i.e. sample 
and separate (bottle/stirrer) or continuous flow (flow through cell apparatus) method. 
2.4.1. Sample and separate method (bottle/stirrer setup)
Ambisome® powder (0.5 mg AmB) was placed into a 100 mL glass bottle (56 mm diameter/ 
105 mm height; Duran, Germany) with 30 mL of release medium and stirred with a magnetic 
stirrer (in a Variomag multipoint stirring plate) at 37°C. Release studies were performed 
based on a two level factorial design of experiments (DoE). The composition of release 
media and agitation conditions used in the DoE are shown in Table 1, the combination of all 
the factors resulted in eight experimental setups.
The agitation rates in the bottle/stirrer setup were selected based on the linear velocity of the 
stirrer edge, which at 130 rpm (10.2 cm/s) is comparable to the linear flow velocities in 
vein/arteries and at 380 rpm (29.5 cm/s) to flow velocities in the aorta (Table 2). 
The concentration of SLS was as described previously [25] to produce clinically relevant 
AmB solubility values (PBS SLS 1.4 mM, KRB SLS 1.5 mM, PBS SLS 60.0 mM BSA 4.0% 
w/v and KRB SLS 30.0 mM BSA 4.0% w/v). In addition to the experimental conditions 
described in Table 1, release studies were also performed in KRB with CTAB and Tween 80 
without BSA at low agitation. The concentration selected was the CMC + 5% CMC of the 
surfactant in KRB (CTAB CMC = 0.2 mM [25], Tween 80 = 10.0 µM [29]) resulting in test 
concentrations of 0.2 mM for CTAB and 10.5 µM for Tween 80. Sampling times were 1, 2, 
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4, 6, 8, and 12 h and after sample treatment (SPE and protein precipitation; section 2.3), 
samples were injected to the HPLC and the % AmB released over time was calculated. All 
experiments were performed in triplicate. 
2.4.2. Continuous flow method (flow-through cell apparatus)
AmB release studies were carried out in a flow-through cell dissolution apparatus (Sotax CE7 
smart connected to a Sotax piston pump CP7, Sotax, Aesch, Switzerland) operated in the 
closed mode [30]. A 5mm ruby glass bead was positioned at the bottom of the cell (large cell: 
22.6 mm diameter). The dialysis membrane was placed into the flow through cell apparatus 
dialysis adapter and Ambisome® powder (0.5 mg AmB) was placed into the membrane with 
1.0 mL of the release medium. Glass fibre filters (GF/D, GF/F) were positioned at the top of 
the cell.
Release studies were performed considering a) biorelevant conditions and b) conditions using 
synthetic surfactants. The biorelevant release studies were based on a two level factorial DoE, 
where the velocity and BSA concentration in KRB (2.0 and 4.0% w/v, representing 
hypoalbuminaemic and healthy subjects, respectively) were the factors investigated. 
Velocities used were considered biorelevant: “Low velocity” (flow rate: 8 mL/min)) is 
comparable to capillary flow and “High velocity” (flow rate: 35 mL/min) is comparable to 
intermediate capillary-vein flow (Table 2). 36 mL of release medium were used in order to 
simulate the equivalent volume available on administration of 1 mg/kg of AmB as 
Amphotericin B® to a 70 kg subject (assuming 5 L of blood volume). Furthermore, as the 36 
mL volume used does not allow for distribution as would happen in vivo, it represents an 
extreme case in terms of available volume.
For studies performed in media with synthetic surfactants PBS SLS 1.4 mM was the release 
medium and the effect of velocity was investigated [medium velocity: 16 mL/min, high 
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velocity: 35 mL/min] and 50 mL of medium were used in order to achieve sink conditions 
(3x saturation solubility) [25].
Samples were taken for up to 12 h and, after sample treatment (if necessary), were injected to 
the HPLC and the %AmB release over time was calculated. All experiments were performed 
in triplicate at 37°C. 
2.5. Release data treatment
Data treatment was previously described [24]. Briefly, for the studies with the sample and 
separate method, %AmB released over time was calculated based on the percent of AmB still 
entrapped in the liposomes at the time of sampling (  (Eq 1) to construct the %𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙)
calculated  profile.%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
(Eq 1) %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 ― %𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙
where  is the mass of AmB placed into the reservoir initially (100%) and %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙
 is the calculated AmB percent released at time . There was no correction for %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑡
degradation for these profiles based on the assumption that the AmB still in the liposome 
cannot be subject of degradation [31].
For the studies with the continuous flow method, %AmB released over time was corrected 
for degradation using the degradation rate constant with Eq 2 to construct the calculated 
 profile.%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
(Eq 2)%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) + 𝑘𝑑𝑒𝑔 ∗ 𝐴𝑈𝐶0 ― 𝑡
where  is the corrected AmB percent released accounting for degradation, %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
 is the AmB percent released at time t,  is the Area Under the %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) 𝐴𝑈𝐶0 ― 𝑡
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Curve of the observed concentration – time curve from time 0 to time  and  is the 𝑡 𝑘𝑑𝑒𝑔
degradation rate constant obtained from the degradation experiments.
First order curve fitting (Eq 3) was performed on the  profiles in order to obtain %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
the release rate constant  (GraphPad Prism 7, GraphPad Software, Inc, USA).(𝑘𝑟𝑒𝑙)
 Eq 3.%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 ∗ (1 ― 𝑒 ― 𝑘𝑟𝑒𝑙𝑡)
where  is time and  is the maximum AmB amount released. The 𝑡 %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥
coefficient of determination (R2) and Akaike information criterion (AIC) were calculated.
 was calculated for all the  profiles.𝐴𝑈𝐶0 ― 12ℎ %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑
2.6. Atomic Force Microscopy (AFM)
To further investigate the effect of proteins and surfactants on the liposomes, AFM studies 
were performed. Ambisome® liposomes were incubated in the following media: KRB, KRB 
BSA 4.0% w/v, KRB SLS 1.5 mM BSA 4.0% w/v (for 30 min) and in KRB CTAB 0.2 mM, 
KRB Tween 10.5 µM and KRB SLS 1.5 mM (for 5 min; a shorter period of incubation was 
set in order to reflect the fast release of AmB from the liposomes observed in the absence of 
BSA). After the incubation, samples were centrifuged for 30 min at 13,300 rpm in an 
Eppendorf centrifuge, the supernatant was discarded and the pellet was dried under vacuum. 
The pellets were diluted with 1 mL of HPLC water, and then 10 µL of the liposomal solution 
was placed on a freshly cleaved mica surface (1.5 cm × 1.5 cm; G250-2 Mica sheets 1″ × 1″ 
× 0.006″; Agar Scientific Ltd., Essex, UK). The sample was then air-dried for ∼30 min and 
imaged immediately by scanning the mica surface in air under ambient conditions using a 
Bruker MultiMode 8 Scanning Probe Microscope (Bruker, Billerica, Massachusetts, USA) 
operated on Peak Force QNM mode. The AFM measurements were obtained using 
ScanAsyst-air probes (Bruker, Billerica, Massachusetts, USA); the spring constant was 
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calibrated by thermal tune (Nominal 0.4 N m−1) and the deflection sensitivity calibrated using 
a silica wafer. AFM scans were acquired at a resolution of 512 × 512 pixels at scan rate of 1 
Hz, and produced topographic images of the samples in which the brightness of features 
increases as a function of height. The raw image data were processed using Bruker 
Nanoscope Analysis (version 1.5), and height images were flattened to remove sample tilt 
and scanner bow. The surface roughness (Ra) of each substrate was determined by using 
Nanoscope Analysis’ algorithm to analyse several scans of the surface from different 
locations (n = 20). AFM images were collected from random spot surface sampling (at least 
four areas). 
2.7. PK modeling for the estimation of the in vivo AmB release rate constant from 
plasma concentration profiles
2.7.1. Data for PK modeling of Ambisome® following administration to healthy subjects 
Published data of plasma concentration profiles from healthy subjects administered 
Fungizone® (AmB deoxycholate formulation, molar fractions: sodium deoxycholate and 
AmB, 0.7 and 0.3 respectively; 5 subjects, 0.6 mg/kg, 2h infusion time [32, 33]) and 
Ambisome® (5 subjects, 2.0 mg/kg, 2h infusion time [34]) where the liposomal and 
released/non-liposomal AmB were quantified and digitalized with Webplot digitalizer 3.8 
software. AmB plasma concentrations obtained after Fungizone® administration, lipid-bound 
AmB and released AmB from the liposomes after the administration of Ambisome®, will be 
referred as free AmB, liposomal AmB and released AmB, respectively.
2.7.2. Workflow for PK modeling and estimation of in vivo release profile
The workflow for the PK modeling to estimate the in vivo release rate constant of AmB from 
Ambisome® ( ) and for model optimization are shown in Figures 1 and 2, respectively.𝑘𝑟𝑒𝑙 ― 𝑖𝑣
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PK parameters for released AmB were estimated based on the parameter estimates of AmB 
following Fungizone® administration.
Compartmental modeling was performed with the excel add-in PKSolver [35] and the 
estimation of , the optimization of the models and the simulations were performed 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
with Berkeley Madonna® 8.3.23 software. The R2 was obtained from observed plasma 
concentration profiles vs predicted plasma concentration profiles of both liposomal and 
released AmB. The in vivo elimination rate constant from liposomal AmB models ( ) 𝑘𝑒𝑙𝐿
comprised the sum of the rate constants of liposomal AmB elimination ( ) and in vivo 𝑘10𝐿
AmB release ( ), i.e.  =  + . 𝑘𝑟𝑒𝑙 ― 𝑖𝑣 𝑘𝑒𝑙𝐿 𝑘10𝐿 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
2.8. Evaluation of the in vitro tests using the PK model
The evaluation of the capacity of the AmB in vitro release tests to predict the in vivo release 
was explored in two parts:
Part A. In vitro release rate constants ( ) (from the profiles that fitted a first-order release 𝑘𝑟𝑒𝑙
profile) were compared to  (mean +/- 1 standard deviation -Table 6).𝑘𝑟𝑒𝑙 ― 𝑖𝑣
Part B. In vivo release profiles were simulated using , using the same dose and 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
available volume as was used in the in vitro release tests to facilitate comparison with in vitro 
data. Three simulated % AmB released profiles were generated using  (mean +/- 1 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
standard deviation), followed by calculation of AUC 0-12h for each profile. 
2.9. Statistical analysis
Pareto charts, based on the DoE analysis, were constructed for the identification of significant 
factors affecting the AUC0-12h obtained from the in vitro release tests. A factor was significant 
when the standardized effect (bars) was larger than the line for statistical significance level (α 
= 0.05) (vertical line). An independent means t – test was performed to compare 2 
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independent means: for the continuous flow studies with PBS SLS 1.4 mM at medium and 
high velocity; in the AFM studies, data were compared against the control sample [KRB 
control (centrifugation/vacuum)]; and for  values from simulated in vivo (as 𝐴𝑈𝐶0 ― 12ℎ
described in section 2.8 part B) and observed in vitro AmB release profiles. A p<0.05 was 
considered significant. Additionally, the 90% confidence interval (90% CI) for the ratio of 
the  geometric means of the measures for the observed in vitro and predicted in 𝐴𝑈𝐶0 ― 12ℎ 
vivo ln  were calculated for in vitro data where the  were not 𝐴𝑈𝐶0 ― 12ℎ 𝐴𝑈𝐶0 ― 12ℎ 
significantly different to the in vivo  data. Data analysis, creation and analysis of 𝐴𝑈𝐶0 ― 12ℎ 
the DoE were performed with the statistical software Statgraphics Centurion XVII (USA) and 
the 90% CI were calculated with IBM SPSS Statistics 25 (USA).
3. Results and discussion
3.1. In vitro release studies of AmB from Ambisome®
3.1.1. Sample and separate method
In vitro release profiles of AmB from Ambisome® using the sample and separate method are 
shown in Figure 3 and their corresponding  values are presented in Table 3. 𝐴𝑈𝐶0 ― 12ℎ
In media with synthetic surfactants, the release is almost complete at the first sampling point 
(1 h) regardless of the buffer or the surfactant tested. Consequently, the statistical analysis of 
release rates could not be performed for the release profiles in synthetic surfactants using the 
sample and separate method. As it is observed in vivo that liposomal AmB is in circulation 
for considerably more than 1 h [34], ~100% release from the liposomes at 1 h would not be 
considered a clinically relevant profile. The statistical analysis of  of the release 𝐴𝑈𝐶0 ― 12h
profiles obtained with the sample and separate method (Figure 4a) shows that the buffer used 
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to prepare the medium does not have any effect on the release, while BSA concentration and 
agitation had a negative and positive effect on AmB release, respectively.
The interaction between BSA concentration and agitation was significant, revealing that even 
though agitation does not affect the release of AmB in media containing BSA 4.0% w/v, at 
high agitation conditions in media with BSA 2.0% w/v, the  is higher than using 𝐴𝑈𝐶0 ― 12ℎ
low agitation. The positive effect of agitation on the release of AmB from the liposomal 
formulation could be attributed to the increased suspension or dispersal of the liposomes and 
thus exposure to the medium, and/or the increased mechanical stress exerted on the liposomes 
(i.e. collision with the bottle wall or the magnetic stirrer). It is interesting that in higher 
agitation conditions the release of AmB from the liposomes in media with a lower BSA 
concentration (2.0% w/v), was higher than in the media with a higher BSA concentration 
(4.0% w/v). BSA seems to provide some kind of protective effect to the liposome, as the 
release of AmB from Ambisome® did not change significantly between both agitation 
conditions when BSA 4.0% w/v was present in the media. Further studies for the 
characterization of this interaction of BSA with the Ambisome® liposomes would provide a 
mechanistic understanding of the release process of AmB from the liposomal formulation.
The release profiles of AmB from liposomes in PBS BSA 2.0% w/v and KRB BSA 2.0% w/v 
at low agitation and PBS BSA 4.0% w/v and KRB BSA 4.0% w/v at high agitation showed 
first order release and the parameters from the first order fitting are listed in Table 4.
3.1.2. Continuous flow method
In vitro release profiles of AmB from Ambisome® obtained using the continuous flow 
method are shown in Figure 5 and their corresponding  values are presented in 𝐴𝑈𝐶0 ― 12ℎ
Table 3. 
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The release of AmB from the liposomes in media incorporating synthetic surfactant (SLS) 
was slower than that observed with the sample and separate method. The slower release 
observed with this setup could be attributed to the use of the dialysis membrane.
The statistical analysis (Figure 4b) showed that the Velocity had a positive effect on the AmB 
release from the liposomes. The BSA*Velocity interaction had a negative effect on the AmB 
release as the release is higher in using the low velocity conditions in the medium with BSA 
4.0% w/v, whereas the BSA concentration on its own was not a significant factor for the 
release. The release data in PBS SLS 1.4 mM show that  is not statistically similar 𝐴𝑈𝐶0 ― 12ℎ
when a high velocity is used compared to the medium velocity. The release profiles of AmB 
from liposomes in KRB BSA 4.0% w/v medium at high velocity and in PBS SLS 1.4 mM at 
both medium and high velocities showed first order release and the parameters from the first 
order fitting are listed in Table 4.
3.2. AFM studies
Figure 6 shows the images obtained from the AFM and Table 5 contains the parameters of 
the liposome characteristics measured by AFM. 
Liposomes could not be seen on the samples from media with SLS and CTAB (Figure 6c and 
6e), probably due to quick disruption of the liposomes in the presence of these surfactants in 
the media, as revealed also by the complete AmB release at the first sampling point in these 
media with the sample and separate method (Figure 3). Liposomes were found in the sample 
with Tween 80 (Figure 6f) as expected by the slightly slower release in this medium. The 
liposomes in the medium with Tween 80 appear to be larger in size and more irregular shaped 
than the control sample, which could reflect occurrence of the reported mechanism of 
surfactant-liposome interaction, with surfactant-saturated vesicles and lipid-saturated 
micelles, which increase the size of the liposomes prior to liposomal disruption [21-23]. The 
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presence of BSA in the media with SLS results in an alteration of the interaction of the SLS 
surfactant with the liposomal structure, as liposomes were present in this sample, revealing 
the interference of the surfactant by BSA (Figure 6d) [36-38]. The liposomes in the sample 
with BSA and SLS were larger in size than those observed in the corresponding sample 
without SLS, possibly due to changes in BSA structure on interaction with SLS, altering the 
form it interacts with the liposome or due to aggregation. Aggregation can be observed in the 
sample with BSA only (Figure 6b) as in the sample with Tween 80, probably due to the same 
process described for SLS BSA. The diameter and surface roughness of the liposomes were 
statistically significantly different to the control sample in KRB BSA 4.0% w/v (for the 
samples in KRB CTAB 0.2 mM and KRB SLS 1.5 mM a statistical comparison was not 
performed as liposomes were not present in these samples, revealing that the charged 
surfactants are able to disrupt the liposomes quickly). These parameters (diameter and surface 
roughness) were not statistically significantly different compared to the control sample for the 
samples in KRB SLS 1.5 mM BSA 4.0 % w/v and KRB Tween 80, revealing that the 
interaction between SLS and BSA changes the way that these molecules interact with the 
liposomes and that the non-ionic surfactant is slightly less aggressive to the liposomes than 
the charged ones. Based on these results it could be considered advisable to conduct AFM 
studies of liposomal size and integrity in a range of dissolution media being considered for 
development of clinically relevant release testing; as observed in the current work the effect 
of the media examined on liposomal size and integrity broadly aligns with the release profiles 
observed.
3.3. PK modeling of in vivo release profiles in healthy subjects 
Observed and predicted in vivo liposomal and released AmB plasma profiles are shown in 
Figure 7. Table 6 shows the PK parameters obtained from compartmental modeling before 
and after model optimization, and the estimated value of . 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
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The liposomal AmB profile for healthy subjects was described by the model developed (R2 = 
0.99). The model for liposomal AmB did not change after the optimization as the only 
relevant parameter is the  which includes  and . The  value was set to 𝑘𝑒𝑙𝐿 𝑘𝑟𝑒𝑙 ― 𝑖𝑣 𝑘10𝐿 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
be lower than  and the difference of the value with  was . After the optimization, 𝑘𝑒𝑙𝐿 𝑘𝑒𝑙𝐿 𝑘10𝐿
the elimination rate constant of released drug ( ) was higher than the initial value. The 𝑘10
difference in the half – life of elimination for AmB from Fungizone® (0.17 ± 0.14 h; 
calculated after poly-exponential fitting) [34] and from Ambisome® (0.66 h; calculated from 
the PK modeling in the current study), reflects the difference in parameter estimates from the 
models fitted to the data obtained following administration of each formulation. As  was 𝑘10
an optimized parameter in the current study, the decrease in the amount of drug in plasma 
could also be due to distribution. A limitation of the model used in the current study is that 
peripheral release of AmB is not included. To our knowledge, the peripheral release kinetics 
are not known. In a situation where peripheral liposomal release was expected to notably 
impact the plasma concentrations, the PK model could be developed to include the peripheral 
release step. In the current work, given the relatively low rate constant reflecting 
redistribution of AmB from the peripheral to the central compartment (Table 6) it is unlikely 
that any peripheral release will have a significant impact on the  estimate in the 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
current model. It is also possible that the lack of a peripheral release step may have partly 
promoted an underestimation of V1; although AmB is highly protein bound, a slightly higher 
V1 for the free AmB than for the liposomal AmB might be expected. Therefore, as with all 
models, there is continued scope for further model optimisation. However, for the purposes of 
illustrating the application of PK modelling in informing the development of a biorelevant in 
vitro release test method, the current model approach is deemed sufficient. 
3.4. Evaluation of clinical relevance of the in vitro release tests 
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3.4.1. Part A. Comparison of in vitro and in vivo release rate constants
The in vitro krel (obtained from the first order fitting of the in vitro release profiles) and the 
 of healthy subjects (obtained from the PK modeling of liposomal and released plasma 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
concentration profiles [34]) are presented in Table 4. Further details on the fittings are 
available in the “Supplementary data” file.
The in vitro krel values are trending higher than the in vivo release rate. However, this analysis 
assumes a first-order release rate in vivo and is hindered by the lack of first order release in 
vitro in several of the test conditions. The in vitro  estimated from the study in PBS BSA 𝑘𝑟𝑒𝑙
4.0% w/v at high agitation conditions was statistically similar to the  of healthy 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
subjects, however this result needs to be interpreted with caution as the coefficient of 
variation for the in vitro  is 75% and the constants could be considered statistically similar 𝑘𝑟𝑒𝑙
due to this high variability. The release rate constants estimated from the studies in media 
with BSA 2% w/v in low agitation conditions are borderline in terms of being statistically 
similar to in vivo values (p-value 0.056-0.058), suggesting potential for further refining in 
vitro conditions to generate release profiles similar to in vivo release profiles. 
3.4.1. Part B. Comparison of in vivo and in vitro 𝑨𝑼𝑪𝟎 ― 𝟏𝟐𝒉
The  of the in vitro release profiles and the in vivo simulated profile (obtained 𝐴𝑈𝐶0 ― 12ℎ
from the developed PK model) are presented in Table 3. 
The simulated %AmB  was 165.18 ± 11.49 (%AmB*h) for healthy subjects. The t-𝐴𝑈𝐶0 ― 12ℎ
test results show that the in vitro  calculated from the %AmB released profiles 𝐴𝑈𝐶0 ― 12ℎ
obtained in media with BSA 4.0% w/v with the sample and separate method were statistically 
similar to the in vivo . With the continuous flow method, the most promising 𝐴𝑈𝐶0 ― 12ℎ
results were generated in media with BSA 2% w/v in low velocity conditions. Despite the 
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fact that the t-test comparisons show that some results were statistically similar, if the 90% 
CIs are compared against the usual bioequivalence interval (80% - 125%) [39], for all the 
90% CIs from sample and separate method with BSA 4.0% w/v, either the lower or upper 
bound was within 80 - 125% which leaves the test as inconclusive but with room for 
improvement (ideally increasing the number of subjects tested). Interestingly, with the 
continuous flow method, BSA 2% w/v in low velocity conditions resulted in an 𝐴𝑈𝐶0 ― 12ℎ 
which could be considered similar to the in vivo AUC based on standard bioequivalence 
comparisons. Along with the krel data in Table 4, this suggests scope to further investigate the 
interplay between hydrodynamics (agitation/velocity) and BSA concentration to identify 
suitable clinically relevant dissolution conditions.
4. Conclusions 
There is a lack of guidance for in vitro release testing of parenteral formulations. In this work, 
factors including medium components and hydrodynamic/agitation conditions were tested to 
understand how they affect drug release from a liposomal formulation for intravenous 
administration (Ambisome®). Regarding hydrodynamics, in both setups tested (sample and 
separate and continuous flow), an increase in the agitation/velocity resulted in significant 
increase of AmB release. The characterization of drug release from liposomes after direct 
contact of synthetic surfactants with the liposomes (sample and separate method) was not 
possible due to fast disruption of the liposomes. The use of the dialysis membrane in the 
continuous flow setup could overcome this issue and allows the use of simple media with 
synthetic surfactants for the characterization of release from these formulations. The presence 
of proteins (BSA) is a critical factor affecting release of drugs with high protein binding 
(such as AmB) with an increasing BSA concentration generally leading to a decrease in drug 
release. A novel approach for the estimation of the in vivo release rate constant from 
liposomes was developed through PK modeling. An in vitro- in vivo relation was developed, 
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with  of in vitro release profiles in media with BSA 4.0% w/v with the sample and 𝐴𝑈𝐶0 ― 12ℎ
separate method being statistically similar to the in vivo calculated . Establishing 𝐴𝑈𝐶0 ― 12ℎ
an in vitro- in vivo relation by using clinically relevant release testing and PK modeling is of 
high importance in order to improve the efficiency of the development and the quality 
evaluation of such formulations.
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Tables
Table 1. Levels and factors investigated with the sample and separate method for the release 
studies of AmB from Ambisome®.
Factors in KRB (no synthetic surfactants added)
Level BSA %w/v Buffer Agitation (rpm)
-1 2.0 PBS 130 (Low Agitation)
+1 4.0 KRB 380 (High Agitation)
Factors in media with synthetic surfactant (SLS)
Level BSA %w/v Buffer Agitation (rpm)
- 1 0.0 PBS 130 (Low Agitation)
+ 1 4.0 KRB 380 (High Agitation)
Table 2. In vivo (bloodstream) and in vitro (flow through cell apparatus with the large cell: 




(flow through cell 
apparatus)










Arteries 3.0 - 26.0 4.9 - 19.0 3.0 - 26.0 0.01 - 0.11
Veins 1.2 - 4.8 1.50 - 7.80 1.2 - 4.8 0.00 - 0.02
Coronary artery 35.0 - 35.0 0.15
Capillaries - 0.03 7.0 0.03
Aorta - 30.0- 40.0 9655.0 40.00
Vena cave - 15.00 3620.0 15.00
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Table 3. %AmB  calculated for all the in vitro release profiles: sample and separate and continuous flow investigating the effect of 𝐴𝑈𝐶0 ― 12ℎ
buffers, BSA concentration, surfactants and agitation and statistical analysis for the comparison of in vitro  and simulated 𝐴𝑈𝐶0 ― 12ℎ 𝐴𝑈𝐶0 ― 12ℎ 
(based on in vivo release rate constant, ) (  = 165.18 ± 11.49 %AmB*h). [for sample and separate; LA: low agitation, HA: high 𝑘𝑟𝑒𝑙 ― 𝑖𝑣 𝐴𝑈𝐶0 ― 12ℎ
agitation. For continuous flow; LV: low velocity, MV: medium velocity, HV: high velocity] (Mean ± SD; n = 3).
Sample and separate method (Bottle/stirrer setup)
Buffer BSA 
(%w/v)




PBS 2.0 LA - 296.04 ± 24.89 <0.05
KRB 2.0 LA - 327.34 ± 23.63 <0.05
PBS 4.0 LA - 176.35 ± 36.09 0.70 80.20 - 138.51
KRB 4.0 LA - 162.14 ± 29.63 0.81 77.03 - 122.87
PBS 2.0 HA - 401.98 ± 28.82 <0.05
KRB 2.0 HA - 409.86 ± 69.55 <0.05
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PBS 4.0 HA - 173.78 ± 24.78 0.65 85.87 - 127.55
KRB 4.0 HA - 146.79 ± 8.11 0.09 79.65 - 99.27
PBS 0.0 LA SLS 1140.67 ± 0.78 <0.05
KRB 0.0 LA SLS 1112.47 ± 1.37 <0.05
PBS 4.0 LA SLS 1136.05 ± 5.95 <0.05
KRB 4.0 LA SLS 1138.21 ± 2.3 <0.05
KRB 0.0 LA Tween 80 1107.72 ± 5.25 <0.05
KRB 0.0 LA CTAB 1137.93 ± 3.23 <0.05
PBS 0.0 HA SLS 1150
KRB 0.0 HA SLS 1117.67 ± 8.98 <0.05
PBS 4.0 HA SLS 1135.18 ± 6.79 <0.05
KRB 4.0 HA SLS 1150
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Continuous Flow method (Flow through cell apparatus)
KRB 2.0 LV - 174.38 ± 15.63 0.46 91.71-121.27
KRB 4.0 LV - 376.23 ± 13.76 < 0.05
KRB 2.0 HV - 745.35 ± 97.47 <0.05
KRB 4.0 HV - 408.91 ± 80.85 < 0.05
PBS 0.0 MV SLS 442.33 ± 129.39 0.06 176.82 - 382.93
PBS 0.0 HV SLS 694.36 ± 124.82 < 0.05
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Table 4. Parameters obtained after fitting (first order equation model) of %AmB released profiles from Ambisome® with the sample and 
separate and the continuous flow method and statistical comparison of in vitro release rate constants and in vivo release rate constants (estimated 
with the PK model for healthy subjects,  = 0.025 ± 0.002 h-1) [for sample and separate; LA: low agitation, HA: high agitation. For 𝑘𝑟𝑒𝑙 ― 𝑖𝑣











PBS 2.0 LA 0.117 ± 0.040 56.07 ± 10.04 0.93 ± 0.04 35.01 ± 2.81 0.056
KRB 2.0 LA 0.214 ± 0.083 44.96 ± 4.88 0.94 ± 0.06 31.99 ± 9.93 0.058
PBS 4.0 HA 0.321 ± 0.245 21.90 ± 4.37 0.85 ± 0.11 30.01 ± 7.03 0.17*
KRB 4.0 HA 0.127 ± 0.021 25.09 ± 3.50 0.86 ± 0.04 29.36 ± 3.11 0.01
Continuous flow
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KRB 4.0 HV 0.467 ± 0.162 43.10 ± 10.56 0.86 ± 0.03 66.54 ± 7.51 0.04
PBS SLS 1.4 mM 0.0 MV 0.725 ± 0.102 41.87 ± 12.27 0.93 ± 0.10 49.69 ± 8.84 0.00
PBS SLS 1.4 mM 0.0 HV 1.547 ± 0.523 60.66 ± 9.09 0.97 54.91 ± 3.18 0.00
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Table 5. Parameters of liposomes obtained from AFM from the samples prepared with the 







KRB control (centrifugation/vacuum) 69.4 ± 18.9 12.9 ± 1.6 11.9
KRB BSA 4.0% w/v 29.0 ± 2.6 4.1 ± 0.2 4.3
KRB SLS 1.5 mM No Particles
KRB SLS 1.5 mM BSA 4.0% w/v 100.0 ± 27.4 10.0 ± 3.1 3.3
KRB CTAB 0.2 mM No Particles
KRB Tween 10.0 µM 81.4 ± 7.7 11.6 ± 2.4 6.4
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Table 6. PK parameters from the compartmental modeling and model optimization from 
liposomal and released AmB after administration to healthy subjects. 
 PK parameters
Population Healthy subjects
AmB form Free Liposomal
V1 (L) 4.830 4.820
V2 (L) 32.486 2.552
initial 0.539 0.155*  (h-1)𝒌𝟏𝟎
optimized 1.052 ± 0.301 0.129 ± 0.002*
 (h-1)𝒌𝟏𝟐 4.955 0.285
 (h-1)𝒌𝟐𝟏 0.737 0.538
initial 0.19 0.99R2
optimized 0.92 ± 0.06 0.99
 (h-1)𝒌𝒓𝒆𝒍 ― 𝒊𝒗 - 0.025 ± 0.002
* For the liposomal AmB,   refers to  ; Similarly V1(L), V2(L), k12, k21 and k10 𝒌𝟏𝟎 𝒌𝟏𝟎𝑳
refer to the relevant parameters for liposomal AmB in the “Liposomal” column i.e. 
Comp1L, Comp2L, k12L, k21L and k10 L respectively. 
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Figure captions
Figure 1. Workflow for the PK modeling of free AmB (Fungizone® administration) and 
liposomal AmB (Ambisome® administration) in order to estimate  (in vivo release rate 𝑘𝑟𝑒𝑙 ― 𝑖𝑣
constant).
Figure 2. Compartmental PK modeling of liposomal AmB and free AmB for the estimation 
of .𝑘𝑟𝑒𝑙 ― 𝑖𝑣
Figure 3. %AmB released as a function of time using the sample and separate method at 
37°C to investigate the effects of buffer, agitation, composition including a) BSA 
concentration and b) type of synthetic surfactant and BSA 4.0% w/v presence) on AmB 
release (Mean ± SD; n = 3). 
Figure 4. Pareto charts for the estimated effects of the main factors and 2 level interactions of 
the analysis of  from a) sample and separate method and b) continuous flow 𝐴𝑈𝐶0 ― 12ℎ
method. A factor was significant when the estimated effect (horizontal bars) was larger than 
the standardized effect (vertical line).
Figure 5. %AmB released as a function of time with the continuous flow method at 37°C in 
KRB to investigate the effects of BSA concentration and velocity, and in PBS SLS 1.4 mM to 
investigate the effect of velocity on AmB release (Mean ± SD; n = 3).
Figure 6. AFM images to evaluate the effect of media components on Ambisome® 
liposomes. a) KRB, b) KRB BSA 4.0% w/v, c) KRB SLS 1.5 mM, d) KRB SLS 1.5 mM 
BSA 4.0% w/v, e) KRB CTAB 0.2 mM and f) KRB Tween 80 10.0 µM. The scale bar 
represents 200 nm.
Figure 7. Observed and predicted liposomal and released AmB plasma profiles simulated 
with the optimized models. Healthy subjects’ data (Bekersky et al, n = 5, [31]), a) Liposomal 
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AmB, b) released AmB. Blue points and line: observed data; red solid lines: mean of the 
prediction, red dotted lines: standard deviation of the prediction.
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